Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for ScreeningMaria Grazia Lazzaroni, Cecília Varjú, Gabriella Nagy et al.|The Journal of Rheumatology|2017Cited by 127
Clinical Characteristics of Anti‐Synthetase Syndrome: Analysis From the Classification Criteria for Anti‐Synthetase Syndrome ProjectSara Faghihi‐Kashani, Raquel Campanilho‐Marques, Akira Yoshida et al.|Arthritis & Rheumatology|2024Cited by 36
OP0031 Risk Factors for Malignancies Synchronous To The Onset of Systemic Sclerosis in Patients Positive for Anti- RNA Polymerase III Antibodies: A Eustar Multicentre StudyMaria Grazia Lazzaroni, Paolo Airó, Ilaria Cavazzana et al.|Annals of the Rheumatic Diseases|2016Cited by 0